Sustained release drug delivery devices

• US 5,902,598 A
• Filed: 08/28/1997
• Issued: 05/11/1999
• Est. Priority Date: 08/28/1997
• Status: Expired due to Term

• Current Assignee: Control Delivery Systems Inc. (EyePoint Pharmaceuticals, Inc.)
• Original Assignee: Control Delivery Systems Inc. (EyePoint Pharmaceuticals, Inc.)
• Inventors: Chen, Jianbing, Ashton, Paul
• Primary Examiner(s): Page, Thurman K.
• Assistant Examiner(s): Seidleck, Brian K.
• Application Number:
  US08/919,221
• Time in Patent Office: 621 Days
• Field of Search: 424/422, 424/423, 424/424, 424/425, 424/427, 604/890.1, 604/891.1, 604/892.1
• US Class Current: 424/423
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61K 9/0092 Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 31/18 for HIV
• CPC Class Codes: A61P 31/22 for herpes viruses
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection

Abstract

A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir comprising the effective agent; a first coating layer, which is permeable to the passage of the effective agent; a second coating layer, which is essentially impermeable to the passage of the effective agent; and a third coating layer, which is permeable to the passage of the effective agent. The first coating layer covers at least a portion of the inner core. The second coating layer covers at least a portion of the first coating layer and inner core; however, at least a small portion of the first coating layer or inner core is not coated with the second coating layer. The second coating layer includes an impermeable film and at least one impermeable disc. The third coating layer essentially completely covers the second coating layer and the uncoated portion of the first coating layer or inner core.

Claims

1. A method for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect comprising:

administering a sustained release drug delivery system to a mammalian organism in need of such treatment, said drug delivery system comprising;

(1) an inner core or reservoir comprising an effective amount of an agent to obtain a desired local or systemic physiological or pharmacological effect,

(2) a first coating layer permeable to the passage of said agent, wherein said first coating layer covers at least a portion of said inner core, which provides control and sustained release of the agent,

(3) a second coating layer, said second coating layer essentially impermeable to the passage of said agent, and said second coating layer covering at least 50% of the inner core and/or the first coating layer, wherein at least a small portion of the inner core or first coating layer is not coated with said second coating layer and said second coating layer comprises an impermeable film and at least one impermeable disc being different material from or having substantially greater hardness, thickness, malleability or response to heat curing than said impermeable film, and

(4) a third coating layer permeable to the passage of said agent, wherein said third coating layer essentially completely covers said second coating layer and the uncoated portion of the first coating layer or inner core, whereby said agent is able to pass through said third coating layer in a controlled manner.

2. A method for treating a mammalian organism as claimed in claim 1, wherein said third coating layer comprises polyvinyl alcohol.

3. A method for treating a mammalian organism as claimed in claim 2, wherein said second coating layer comprises ethylene vinyl acetate.

4. A method for treating a mammalian organism as claimed in claim 3, wherein said first coating layer comprises polyvinyl alcohol.

5. A method for treating a mammalian organism as claimed in claim 1, wherein said effective agent comprises fluocinolone acetonide, nimodipine or ganciclovir.

24. A method for treating a mammalian organism according to claim 1, wherein said impermeable film is made of a composition different from said impermeable disc.

25. A method for treating a mammalian organism as claimed in claim 1, wherein said second coating layer covers all of the inner core and first coating layer except for a diffusion port opening.

26. A method for treating a mammalian organism as claimed in claim 1, wherein said impermeable disc is harder than said impermeable film.

6. A method for treating a mammalian organism for cytomegalovirus retinitis comprising:

administering a sustained release drug delivery system to a mammalian organism in need of such treatment, said drug delivery system comprising;

(1) an inner core or reservoir comprising an effective amount of ganciclovir effective to obtain a desired local or systemic physiological or pharmacological effect,

(2) a first coating layer permeable to the passage of said agent, said first coating layer essentially completely covers said inner core,

(3) a second coating layer, said second coating layer essentially impermeable to the passage of said ganciclovir, and said second coating layer covering at least 50% of the inner core and/or the first coating layer, wherein at least a small portion of the inner core or first coating layer is not coated with said second coating layer, and wherein said second coating layer comprises an impermeable film and at least one impermeable disc being a different material from or having substantially greater hardness, thickness, malleability or response to heat curing than said impermeable film, and

(4) a third coating layer permeable to the passage of said ganciclovir, wherein said third coating layer essentially completely covers said second coating layer and the uncoated portion of the first coating layer or inner core, whereby said ganciclovir is able to pass through said third coating layer in a controlled manner.

7. A method for providing controlled and sustained administration of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect comprising:

surgically implanting a sustained release drug delivery system at a desired location, said drug delivery system comprising;

(1) an inner core or reservoir comprising an effective amount of an agent effective in obtaining a desired physiological or pharmacological effect, and

(2) a first coating layer permeable to the passage of said agent, wherein said first coating layer covers at least a portion of said inner core, which provides control and sustained release of the agent,

(3) a second coating layer, said second coating layer essentially impermeable to the passage of said agent, and said second coating layer covering at least 50% of the inner core and/or the first coating layer, wherein at least a small portion of the inner core or first coating layer is not coated with said second coating layer and said second coating layer comprises an impermeable film and at least one impermeable disc being a different material from or having substantially greater hardness, thickness, malleability or response to heat curing than said impermeable film, and

(4) a third coating layer permeable to the passage of said agent, wherein said third coating layer essentially completely covers said second coating layer and the uncoated portion of the first coating layer or inner core, whereby said agent is able to pass through said third coating layer in a controlled manner.

8. A method as claimed in claim 7, wherein said device is surgically implanted within the vitreous of the eye.

9. A method as claimed in claim 7, wherein said first and third coating layers comprise polyvinyl alcohol.

10. A method as claimed in claim 7 wherein said third coating layer is silicone.

11. A method as claimed in claim 9, wherein said second coating layer comprises ethylene vinyl acetate.

12. A method as claimed in claim 11, wherein said effective agent is ganciclovir or 5-fluorouracil.

13. A method as claimed in claim 11 wherein said effective agent is a low solubility steroid.

14. A method as claimed in claim 13, wherein said low solubility steroid is fluocinolone acetonide.

15. A method as claimed in claim 11 wherein said effective agent is a neuroprotectant.

16. A method as claimed in claim 15, wherein said neuroprotectant is nimodipine.

17. A sustained release drug delivery system comprising:

(A) an inner core or reservoir comprising an effective amount of an agent effective in obtaining a desired local or systemic physiological or pharmacological effect,

(B) a first coating layer permeable to the passage of said agent, wherein said first coating layer covers at least a portion of said inner core, which provides control and sustained release of the agent,

(C) a second coating layer, said second coating layer impermeable to the passage of said effective agent, and said second coating layer covering at least 50% of the inner core and/or the first coating layer wherein at least a small portion of the inner core or first coating layer is not coated with said second coating layer and said second coating layer comprises an impermeable film and at least one impermeable disc being a different material from or having substantially greater hardness, thickness, malleability or response to heat curing than said impermeable film, and

(D) a third coating layer, said third coating layer permeable to the passage of said effective agent, wherein said third coating layer essentially completely covers the second coating layer and the uncoated portion of the first coating layer or inner core.

18. A sustained release drug delivery system as claimed in claim 17, wherein said third coating layer comprises polyvinyl alcohol.

19. A sustained release drug delivery system as claimed in claim 18, wherein said second coating layer comprises ethylene vinyl acetate.

20. A sustained release drug delivery system as claimed in claim 19, wherein said first coating layer comprises polyvinyl alcohol.

21. A sustained release drug delivery system as claimed in claim 20, wherein said effective agent is ganciclovir or fluocinolone acetonide.

22. A sustained release drug delivery system as claimed in claim 17, wherein said effective agent is nimodipine.

23. A sustained release drug delivery system as claimed in claim 17, wherein the third coating layer comprises silicone.

27. The sustained release drug delivery system as claimed in claim 17, wherein said effective agent is a steroid.

28. The sustained drug delivery system as claimed in claim 17, wherein said effective agent is a neuroprotectant.